No Modulation of Circulating Natural Killer Cell and Natural Killer Receptor Bearing Memory T Cell Subsets in Patients with Atopic Dermatitis  by Bouloc, Anne et al.
developing any NMSC. Multivariable Cox models were used to
control for some potential confounders (gender, age, smoking,
incident warts).
At the end of follow-up (161 mo), 33 patients had developed
either SCC, BCC, or both. All patients with ST-I developed at
least one NMSC. This proportion was 53% for ST-II, 13% for
ST-III, and none for ST-IV (only four patients). The higher
the TSB was, the higher was the incidence of SCC and BCC
(Table I). The group with highest TSB previous to transplant
exhibited highly signi®cant adjusted relative risks for SCC
(19.86), BCC (6.08), and any of both (13.71) (Table I). The
relative risk reduction associated with having a ST III/IV were
87% (SCC), 62% (BCC), and 83%, for any of them (Table I).
This estimate was not signi®cant for BCC. Contrary to what
was expected, the development of warts after the heart
transplant was not predictive of a higher risk of SCC or
BCC, and even an inverse association was found for any of
them (p = 0.02). When we considered deaths as events the
results did not substantially change (data not shown).
The cumulative absolute risk of developing any NMSC by joint
categories of exposure to TSB and ST was shown to be highly
predictive (Table II). We also estimated the adjusted relative
hazards for each joint category of TSB and ST, but we used as the
reference the merging of two strata (total: 70 patients) with score
< 10 for TSB and ST III/IV. The relative risks were 4.15 for ST
III/IV and TSB > 10; 8.67 for ST I/II and TSB = 6±10, and 20.19
for ST I/II and TSB score > 10.
Our study, which included a follow-up longer than previously
published reports (Olivari et al, 1990; EspanÄa et al, 1995; Euvrard
et al, 1995; Jensen et al, 1999), identi®ed two major risk factors
explaining the high incidence of NMSC in HRT: ST and the total
amount of exposure to sunlight, previously to the transplant. In
addition, our data do not support the consideration of viral warts as
an early marker for tumor development among HTR.
In the general population of Spain (Zubiri et al, 1981), the ratio
SCC/BCC is 0.3/1. We found a slightly higher incidence of BCC
during the earlier period of follow-up, but progressively the ratio of
SCC/BCC was reversed, reaching 1.66/1 at the end of the study.
There are few published studies assessing the role of ST in
determining the risk of NMSC among HTR and among transplant
recipients in general (McLelland et al, 1988). Our main results lead
us to think that patients who are candidates for heart transplant and
have a ST I or II will experience extremely high rates of NMSC in
the long run. This risk must be taken into account for thoroughly
balancing it against the potential bene®ts of a heart transplant.
Our results also support the importance of TSB previously to
receiving the transplant. We provide strong evidence to recom-
mend that when patients with a high TSB receive a transplant, they
must undergo an especially stringent dermatologic surveillance for
skin cancer.
The system we have used to score TSB in HTR has been
shown to predict rates of developing NMSC in these patients.
When combined with the ST, it can be used as a practical
approach for classifying HRT according to their risk of
developing these malignancies. This information could help
improve the setting of priorities in selecting patients for heart
transplant; however, we acknowledge that an external prospec-
tive validation of this scoring system with a different series of
patients is needed.
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No Modulation of Circulating Natural Killer Cell and Natural
Killer Receptor Bearing Memory T Cell Subsets in Patients
with Atopic Dermatitis
To the Editor:
Atopic dermatitis (AD) is a chronic in¯ammatory skin disease with
abnormalities of both cell-mediated and humoral immunity, and
increased susceptibility to cutaneous infections. Natural killer cells
provide a ®rst line of defence against virus. The aim of our study
was to determine the characteristics of circulating natural killer
receptor bearing cells in patients with AD.
Two families of natural killer receptor molecules have been
identi®ed in humans. The ®rst are type I transmembrane proteins
belonging to the Ig superfamily, such as p58.1/CD158a, p58.2/
CD158b (Moretta et al, 1993), p70/CD158d (Litwin et al, 1994),
p140/CD158j (Pende et al, 1996), and BY 55/CD160
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(Anumanthan et al, 1998), and the second are the type II
transmembrane proteins containing a C-type lectin domain, such
as the heterodimer CD94/NKG2 (Moretta et al, 1994). These
natural killer receptors that can be expressed as two distinct
isoforms, may inhibit or activate the cytolytic function by
interaction with distinct polymorphic epitopes of major histocom-
patibility (MHC) class I molecules or nonclassical MHC class I
molecules such as HLA-E (Braud et al, 1998). Most of the known
natural killer receptors have been identi®ed through studies of
natural killer cells, but natural killer receptors were also found to be
expressed by a minor population of T cells mainly from the CD8
subset (Phillips et al, 1995). The natural killer receptors within the
natural killer cell population are clonally distributed. In addition, T
cells expressing natural killer receptors populations were found to
be mono- or oligoclonal, as indicated by very limited diversity of T
cell receptor rearrangements (Mingari et al, 1996). It was postulated
that these T cells may represent memory T lymphocytes
(Cambiaggi et al, 1999).
In patients with AD, functional and phenotypic studies on
natural killer subsets have yielded con¯icting results. (i) Natural
killer cell activity against the standard natural killer-sensitive target
cells, i.e., K562 cells studied in patients with AD was found normal
(Viander et al, 1982); however, opposite ®ndings have also been
reported and signi®cant reduction in natural killer cell activity was
found in patients with AD (Jensen et al, 1984; Lever et al, 1984;
Hall et al, 1985). These later authors suggested that the reduced
natural killer cell activity may be secondary to chronic skin disease,
and due to in vivo interaction between natural killer cells and
monocytes, or to low numbers of natural killer cells in peripheral
blood. (ii) In addition, phenotypic analysis revealed lower
percentages of peripheral blood cells with CD16, CD56 natural
killer surface antigens in patients with AD for some authors
(Wehrmann et al, 1990; Walker et al, 1993; Goodyear et al, 1996).
In contrast, others reported no differences in age-matched
peripheral blood samples of AD patients, other atopic patients,
and healthy control subjects with respect to the general proportions
of natural killer cells among total circulating lymphocytes (Dworzak
et al, 1999).
We performed an extended immunophenotypic analysis using
¯ow cytometry to determine the characteristics of circulating
natural killer cells and memory T cells expressing natural killer
receptors in patients with AD and in healthy controls. We
evaluated 11 adult patients aged 18±37 y old with severe AD
(SCORAD range 48±86) who had a ¯are of AD and had not been
treated with corticosteroids for at least 15 d. We compared them
with seven sex-matched age-matched controls who had no
personal or family history of atopy. PE-labeled antibodies speci®c
for p58.1/CD158a, p58.2/CD158b, CD94, CD56, ECD-labeled
anti-CD3 antibodies as well as isotype control antibodies were
purchased from Immunotech-Beckman (Marseilles, France). Other
MoAb used in the study were either produced locally for BY55/
CD160 or kindly obtained from Pr Moretta (University of Genova,
Italy) for p140/CD158j. Peripheral blood mononuclear cells were
separated from heparinized blood by centrifugation on Ficoll; cells
were washed in ¯ow cytometry buffer (PBS, 5% fetal calf serum,
0.02% sodium azide), stained for 30 min at 4°C with the antibodies
at saturation, washed three times, and analyzed on a Coulter Epics
cytometer, according to standard procedures.
No difference in percentages of circulating T cells de®ned by
CD3 staining or circulating natural killer cells de®ned by CD56
staining in patients with AD compared with nonatopic controls was
detectable (Table I). Within the T population, there was no
difference regarding the memory T cell subset de®ned by natural
killer receptor expression. Within the natural killer population,
there was no difference within the subsets de®ned by speci®c
natural killer receptors. In addition, we could not see any alteration
in natural killer function using the K562 read-out assay (data not
shown). These data indicate that there was no signi®cant
modulation of circulating natural killer receptor expressing cells
in patients with severe form of AD.
Anne Bouloc,*² Dominique Charue,* Maria Nikolova,*
Armand Bensussan*
*INSERM U448, Paris XII University, CreÂteil, France
²Department of Dermatology, AP-HP, HoÃpital Henri-Mondor,
Paris XII University, CreÂteil, France
REFERENCES
Anumanthan A, Bensussan A, Boumsell L, et al: Cloning of BY55, a novel Ig
superfamily member expressed on natural killer cells, CTL and intestinal
intraepithelial lymphocytes. J Immunol 161:2780±2790, 1998
Braud VM, Allan DS, O'Callaghan CA, et al: HLA-E binds to natural killer cell
receptors CD94/NKG2A, B and C. Nature 391:795±799, 1998
Cambiaggi A, Darche S, Guia S, Kourilsky P, Abastado JP, Vivier E: Modulation of
T-cell functions in KIR2DL3 (CD158b) transgenic mice. Blood 94:2396±2402,
1999
Dworzak MN, Froschl G, Printz D, et al: Skin-associated lymphocytes in the
peripheral blood of patients with atopic dermatitis: signs of subset expansion
and stimulation. J Allergy Clin Immunol 103:901±906, 1999
Goodyear HM, McLeish P, Randall S, et al: Immunological studies of herpes simplex
virus infection in children with atopic eczema. Br J Dermatol 134:85±93, 1996
Hall TJ, Rycroft R, Brostoff J: Decreased natural killer cell activity in atopic eczema.
Immunology 56:337±344, 1985
Jensen JR, Sand TT, Jorgensen AS, Thestrup-Pedersen K: Modulation of natural
killer cell activity in patients with atopic dermatitis. J Invest Dermatol 82:30±34,
1984
Lever RS, Lesko MJ, Mackie RM, Parrott DM: Natural-killer-cell activity in atopic
dermatitis. Clin Allergy 14:483±490, 1984
Litwin V, Gumperz J, Parham P, Phillips JH, Lanier LL: NKB1: a natural killer cell
receptor involved in the recognition of polymorphic HLA-B molecules. J Exp
Med 180:537±543, 1994
Mingari MC, Schiavetti F, Ponte M, et al: Human CD8+ T lymphocyte subsets that
express HLA class I-speci®c inhibitory receptors represent oligoclonally or
monoclonally expanded cell populations. Proc Natl Acad Sci USA 93:12433±
12438, 1996
Moretta A, Vitale M, Bottino C, et al: P58 molecules as putative receptors for major
histocompatibility complex (MHC) class I molecules in human natural killer
(NK) cells. Anti-p58 antibodies reconstitute lysis of MHC class I-protected
cells in natural killer clones displaying different speci®cities. J Exp Med
178:597±604, 1993
Moretta A, Vitale M, Sivori S, et al: Human natural killer cell receptors for HLA-class
I molecules. Evidence that the Kp43 (CD94) molecule functions as receptor for
HLA-B alleles. J Exp Med 180:545±555, 1994
Pende D, Biassoni R, Cantoni C, et al: The natural killer cell receptor speci®c
for HLA-A allotypes: a novel member of the p58/p70 family of inhibitory
receptors that is characterized by three immunoglobulin-like domains and is
expressed as a 140-kD disulphide-linked dimer. J Exp Med 184:505±518,
1996
Phillips JH, Gumperz JE, Parham P, Lanier LL: Superantigen-dependent, cell-
mediated cytotoxicity inhibited by MHC class I receptors on T lymphocytes.
Science 268:403±405, 1995
Viander M, Uksila J, Lassila O, Jansen CT: Natural killer cell activity in atopic
dermatitis. Arch Dermatol Res 274:283±288, 1982
Walker C, Kagi MK, Ingold P, Braun P, Blaser K, Bruijnzeel-Koomen CA,
Table I. No modulation of circulating natural killer cell and
natural killer receptor bearing memory T cell subsets in
patients with AD could be evidenced using ¯ow cytometric
analysisa
% Controls Patients
mean 6 SD mean 6 SD
CD3 75 6 9.6 78.4 6 9.6
CD56 17.5 6 8.4 11.4 6 4.4
CD94 16.8 6 7.3 15.5 6 9.4
CD158a 5.7 6 5.6 10.5 6 7
CD168b 5.8 6 4.8 9.3 6 5.3
CD158j 3.6 6 4.3 6.2 6 7.8
CD160 14.1 6 5.8 11.5 6 7.1
CD3 CD56 6.1 6 4.6 4.4 6 2.6
CD3 CD94 6.7 6 4.8 4.4 6 2.7
CD3 CD158a 2.2 6 2.3 6.8 6 5.9
CD3 CD158b 2.5 6 1.3 4.3 6 4.2
CD3 CD158j 1.4 6 1.9 2.5 6 4.4
CD3 CD160 5.1 6 2.9 4.7 6 4.8
aNone of the values between atopic dermatatis patients and nonatopic controls
were signi®cantly different (Student's t test).
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Lack of Association Between Promoter Polymorphism of the
Tumor Necrosis Factor-a Gene and Psoriatic Arthritis in
Japanese Patients
To the Editor:
The analysis of population-speci®c human leukocyte antigen
(HLA) has provided evidence that susceptibility to psoriasis is
linked to HLA with racial differences (Henseler, 1997). Tumor
necrosis factor-a (TNF-a) gene is also mapped within the HLA
region and its product has been reported as one of the most
important cytokines in the pathogenesis of psoriasis (Uyemura
et al, 1993). Recently, HoÈhler et al (1997) reported in this
journal a signi®cant increase of subjects carrying A at position -
238 of TNF-a gene promoter region in the psoriatic arthritis
(PsA) group, as well as in that of early-onset psoriasis vulgaris
(PsV). These ®ndings, however, are still controversial (Jacob
et al, 1999; HoÈhler, 1999). Jacob et al (1999) have also shown in
the journal that promoter polymorphism at -238 of the TNF-a
gene was not associated with early onset PsV when tested by
the transmission disequilibrium test. Very recently, it has been
demonstrated that an increased frequency of the TNF-238.A (A
at -238) allele detected only in male patients but not in female
patients with early-onset PsV (Reich et al, 2000). On the other
hand, there are only a few reports on whether polymorphism of
the TNF-a promoter region and PsA are associated or not,
because only a few cases are investigated. Moreover, three new
polymorphisms at positions -1031 (T to C change), -863 (C to
A), and -857 (C to T) have been identi®ed in the Japanese
population (Higuchi et al, 1998). In this study we evaluated the
association between promoter polymorphism of the TNF-a
gene and PsA in the Japanese population.
Twenty Japanese patients (eight females and 12 males)
suffering from PsA were studied (the median age was 44 y,
ranged from 25 to 70). The control population consisted of 87
locally recruited, unrelated volunteers (21 female and 67 males
with a median age of 52 y ranged from 15 to 81). Peripheral
blood mononuclear cells were separated by the Ficoll method
for isolation of genomic DNA. A 1042 bp DNA fragment of
the 5¢ ¯anking region of the TNF-a gene at position -1107 to
-66 was ampli®ed by PCR with a sense primer 5¢-
GCTTGTGTGTGTGTGTCTGG-3¢ and an anti-sense primer
5¢-GGACACACAAGCATCAAGG-3¢ (Higuchi et al, 1998).
Polymerase chain reaction (PCR) products were run on
ethidium bromide-stained agarose gel, and then excised DNA
bands from the gel were puri®ed using a GENECLEAN II kit
(BIO 101, La Jolla, CA). These puri®ed PCR products were
directly sequenced by the dideoxy nucleotide dye terminator
cycle sequencing method using two different primers, 5¢-
GCTTGTGTGTGTGTGTCTGG-3¢ (Higuchi et al, 1998) for
the polymorphism at -1031, -863, and -857, and 5¢-
TTCCTGCATCCTGTCTGGAA-3¢ (D'Alfonso and Richiardi,
1994) for those at -308 and -238, respectively.
As shown in Table I, all patients with PsA studied have a
genotype G/G at both -238 and -308, whereas 4.6% (four of 87)
and 3.4% (three of 87) of controls have a genotype G/A at -238 and
-308, respectively. Gene frequencies for the TNF-238A allele in
the Japanese controls were similar to those reported by the authors
for West European Caucasians (2.3% vs 3.5%) (HoÈhler et al, 1997)
and the previous report for Japanese patients (2.3% vs 2.0%)
(Higuchi et al, 1998). The frequencies for the TNF-308A (A at
-308) allele in the Japanese controls, however, were less than those
reported by the authors for West European Caucasians (2.9% vs
10%) (HoÈhlet et al, 1997), whereas no difference was seen between
this study and the previous one (2.9% vs 1.7%) (Higuchi et al,
1998). Furthermore, we found no signi®cant increase of subjects
carrying C, A, and T at positions -1031, -863, and -857,
respectively (Table I). In this region the frequency of alleles
-1031C (C at -1031), -863A (A at -863), and -857T (T at -857) is
similar to that previously reported by Higuchi et al (1998) (12.6% vs
16.0% for -1031C; 15.5% vs 14.0%, -863A; 15.5% vs 17.7%,
-857T).
These results are quite different from those reported by
HoÈhler et al (1997). In their report, 32% (20 in 62) of PsA
patients have genotype G/A at -238, whereas 7% of controls
(seven of 99) have the genotype (HoÈhler et al, 1997). We
calculated on gene frequencies for the TNF-238A allele in PsA
patients 16.1% from the data demonstrated. The discrepancy
does not seem to depend on the racial difference, because gene
frequencies for the TNF-238A allele in their controls were not
different from the data by our or other studies (3.5% vs 2.3% or
2.0%) (HoÈhlet et al, 1997; Higuchi et al, 1998). Although a small
number of PsA cases was investigated, this study clearly shows
that promoter polymorphism at -238 of the TNF-a gene is not
associated with PsA in the Japanese population as well as at
other positions, including -1031, -863, -857, and -308.
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